Zealand Pharma Reports Positive Phase 1 Results for ZP9830
Zealand Pharma announced positive topline results from the multiple ascending dose part of its Phase 1 trial of the Kv1.3 ion channel blocker ZP9830.
Story updates
05:02:37 AM UTC
SquawkNews
Zealand Pharma A/S reported its Kv1.3 blocker ZP9830 was safe and well tolerated in a 4-week multiple ascending dose Phase 1 trial, with no dose-limiting safety findings and supportive PK. A Phase 1b psoriasis study is underway.Material DetailsContext by AI AnalystThis is an early-stage safety de-r…